Guardant Health (GH) Tops Q4 EPS by 16c; offers guidance

Guardant Health (NASDAQ: GH) reported Q4 EPS of ($0.62), $0.16 better than the analyst estimate of ($0.78). Revenue for the quarter came in at $201.8 million versus the consensus estimate of $186.78 million.

GUIDANCE:

Guardant Health sees FY2025 revenue of $850-860 million, versus the consensus of $850.3 million.

For earnings history and earnings-related data on Guardant Health (GH) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Evolution Petroleum to buy Midland Basin mineral rights for $16M
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance